How is Semaglutide administered?
This describes how Semaglutide is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once weekly schedule, generally over open-ended, titrate over months. Specific dosing is individual and beyond general information, and human evidence for Semaglutide is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once weekly
- Cycle length: Open-ended, titrate over months
- Half-life: ~7 days
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1) — Wilding JPH et al., NEJM, 2021
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — Lincoff et al., N Engl J Med, 2023
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — Marso et al., N Engl J Med, 2016
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Semaglutide
Full Semaglutide breakdownSemaglutide what it's used forSemaglutide side effectsSemaglutide mistakes to avoidSemaglutide who should avoid itSemaglutide half-lifeSemaglutide how long to workSemaglutide legal statusSemaglutide how it workstirzepatide vs semaglutidesemaglutide vs cagrilintidesemaglutide vs retatrutidesemaglutide vs mazdutideAsk the AI Coach
Last updated 2026-06-15.